| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2503-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2545-114
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2537-143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-00 |
| filingDate |
2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010518811-A |
| titleOfInvention |
Methods for determining cancer resistance to histone deacetylase inhibitors |
| abstract |
Methods and compositions for determining whether a particular cancer is resistant or susceptible to one histone deacetylase inhibitor or multiple histone deacetylase inhibitors are described herein. The This method involves analysis of the expression levels of at least four biomarker genes associated with a response to a histone deacetylase inhibitor. Also provided are methods and compositions for increasing the likelihood of therapeutically effective treatment in a patient comprising analyzing the expression levels of at least four biomarker genes associated with a response to a histone deacetylase inhibitor. Described herein. Also described herein are isolated populations of nucleic acids derived from cancers that are sensitive or resistant to histone deacetylase inhibitors. In addition, kits and indicators for use with the methods and compositions described above are described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9421208-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019076114-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015515279-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10105552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014221049-A |
| priorityDate |
2007-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |